UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years

The New England journal of medicine, 2017-11, Vol.377 (19), p.1836-1846

2017

Volltextzugriff (PDF)

Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer

Nature communications, 2020-05, Vol.11 (1), p.2662-2662, Article 2662

2020

Volltextzugriff (PDF)

11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial

The Lancet (British edition), 2017-03, Vol.389 (10075), p.1195-1205

2017

Volltextzugriff (PDF)

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial

The lancet oncology, 2010-12, Vol.11 (12), p.1135-1141

2010

Volltextzugriff (PDF)

Current and emerging biomarkers in breast cancer: prognosis and prediction

Endocrine-related cancer, 2010-12, Vol.17 (4), p.R245-R262

2010

Volltextzugriff (PDF)

Biomarkers for the clinical management of breast cancer: International perspective

International journal of cancer, 2013-07, Vol.133 (1), p.1-13

2013

Volltextzugriff (PDF)

Influence of Sex Hormones on Cancer Progression

Journal of clinical oncology, 2010-09, Vol.28 (26), p.4038-4044

2010

Volltextzugriff (PDF)

Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer

Journal of clinical oncology, 2016-09, Vol.34 (25), p.2961-2968

2016

Volltextzugriff (PDF)

Clinical validity of clinical treatment score 5 (CTS5) for estimating risk of late recurrence in unselected, non-trial patients with early oestrogen receptor-positive breast cancer

Breast cancer research and treatment, 2021-02, Vol.186 (1), p.115-123

2021

Volltextzugriff (PDF)

Comparison of PAM50 Risk of Recurrence Score With Oncotype DX and IHC4 for Predicting Risk of Distant Recurrence After Endocrine Therapy

Journal of clinical oncology, 2013-08, Vol.31 (22), p.2783-2790

2013

Volltextzugriff (PDF)

Combined quantitative measures of ER, PR, HER2, and KI67 provide more prognostic information than categorical combinations in luminal breast cancer

Modern pathology, 2019-09, Vol.32 (9), p.1244-1256

2019

Volltextzugriff (PDF)

Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer

Cancer research (Chicago, Ill.), 2016-04, Vol.76 (8), p.2301-2313

2016

Volltextzugriff (PDF)

Emerging Biomarkers and New Understanding of Traditional Markers in Personalized Therapy for Breast Cancer

Clinical cancer research, 2008-12, Vol.14 (24), p.8019-8026

2008

Volltextzugriff (PDF)

Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer

Science translational medicine, 2015-08, Vol.7 (302), p.302ra133

2015

Volltextzugriff (PDF)

Factors Predicting Late Recurrence for Estrogen Receptor―Positive Breast Cancer

JNCI : Journal of the National Cancer Institute, 2013-10, Vol.105 (19), p.1504-1511

2013

Volltextzugriff (PDF)

Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update

Journal of clinical oncology, 2013-11, Vol.31 (31), p.3997-4013

2013

Volltextzugriff (PDF)

Mechanisms of tamoxifen resistance

Endocrine-related cancer, 2004-12, Vol.11 (4), p.643-658

2004

Volltextzugriff (PDF)

Proliferation Marker Ki-67 in Early Breast Cancer

Journal of clinical oncology, 2005-10, Vol.23 (28), p.7212-7220

2005

Volltextzugriff (PDF)

Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial

The Lancet (British edition), 2014-03, Vol.383 (9922), p.1041-1048

2014

Volltextzugriff (PDF)

Prediction of late distant recurrence after 5 years of endocrine treatment: a combined analysis of patients from the Austrian breast and colorectal cancer study group 8 and arimidex, tamoxifen alone or in combination randomized trials using the PAM50 risk of recurrence score

Journal of clinical oncology, 2015-03, Vol.33 (8), p.916-922

2015

Volltextzugriff (PDF)

Digital mammographic density and breast cancer risk: a case-control study of six alternative density assessment methods

Breast cancer research : BCR, 2014-09, Vol.16 (5), p.439-439, Article 439

2014

Volltextzugriff (PDF)

Prognostic Value of a Combined Estrogen Receptor, Progesterone Receptor, Ki-67, and Human Epidermal Growth Factor Receptor 2 Immunohistochemical Score and Comparison With the Genomic Health Recurrence Score in Early Breast Cancer

Journal of clinical oncology, 2011-11, Vol.29 (32), p.4273-4278

2011

Volltextzugriff (PDF)

HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity

Modern pathology, 2014-01, Vol.27 (1), p.4-18

2014

Volltextzugriff (PDF)

Effect of Body Mass Index on Recurrences in Tamoxifen and Anastrozole Treated Women: An Exploratory Analysis From the ATAC Trial

Journal of clinical oncology, 2010-07, Vol.28 (21), p.3411-3415

2010

Volltextzugriff (PDF)

Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population

The lancet oncology, 2013-10, Vol.14 (11), p.1067-1076

2013

Volltextzugriff (PDF)

1 – 25 von 527

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(521)
Mit Volltextzugriff
(506)

Publikationsform

Artikel
(513)
Tagungsberichte
(14)

Sprache

Englisch
(526)
Russisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(373)
Life Sciences & Biomedicine
(366)
Humans
(359)
Female
(333)
Oncology
(285)
Breast Neoplasms - Drug Therapy
(191)
Breast Cancer
(185)
Biological And Medical Sciences
(176)
Medical Sciences
(168)
Tumors
(166)
Middle Aged
(145)
Breast Neoplasms - Genetics
(122)
Aged
(121)
Breast Neoplasms - Pathology
(121)
Gynecology. Andrology. Obstetrics
(102)
Mammary Gland Diseases
(101)
Breast Neoplasms - Metabolism
(94)
Prognosis
(83)
Antineoplastic Agents, Hormonal - Therapeutic Use
(79)
Adult
(78)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years

Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer

11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial

Current and emerging biomarkers in breast cancer: prognosis and prediction

Biomarkers for the clinical management of breast cancer: International perspective

Influence of Sex Hormones on Cancer Progression

Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer

Clinical validity of clinical treatment score 5 (CTS5) for estimating risk of late recurrence in unselected, non-trial patients with early oestrogen receptor-positive breast cancer

Comparison of PAM50 Risk of Recurrence Score With Oncotype DX and IHC4 for Predicting Risk of Distant Recurrence After Endocrine Therapy

Combined quantitative measures of ER, PR, HER2, and KI67 provide more prognostic information than categorical combinations in luminal breast cancer

Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer

Emerging Biomarkers and New Understanding of Traditional Markers in Personalized Therapy for Breast Cancer

Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer

Factors Predicting Late Recurrence for Estrogen Receptor―Positive Breast Cancer

Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update

Mechanisms of tamoxifen resistance

Proliferation Marker Ki-67 in Early Breast Cancer

Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial

Prediction of late distant recurrence after 5 years of endocrine treatment: a combined analysis of patients from the Austrian breast and colorectal cancer study group 8 and arimidex, tamoxifen alone or in combination randomized trials using the PAM50 risk of recurrence score

Digital mammographic density and breast cancer risk: a case-control study of six alternative density assessment methods

Prognostic Value of a Combined Estrogen Receptor, Progesterone Receptor, Ki-67, and Human Epidermal Growth Factor Receptor 2 Immunohistochemical Score and Comparison With the Genomic Health Recurrence Score in Early Breast Cancer

HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity

Effect of Body Mass Index on Recurrences in Tamoxifen and Anastrozole Treated Women: An Exploratory Analysis From the ATAC Trial

Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population

Suchergebnisse filtern